Synvect
United States
- San Diego, CA
- 14/03/2025
- Seed
- $3,000,000
A biotechnology platform to develop safe, scalable, and effective solutions to eliminate disease-transmitting vectors, starting with the world's deadliest animal: the mosquito.
- Industry Biotechnology Research
- Website https://www.synvect.com/
- LinkedIn https://www.linkedin.com/company/synvect/
Related People
Nikolay KandulCo Founder
United States -
San Diego, California
Nikolay is the co-founder and CEO of Synvect, a company dedicated to developing and commercializing next-generation, safe, and effective products for the biological elimination of mosquitoes. These innovative solutions aim to block the transmission of mosquito-borne diseases and eliminate biting nuisances, advancing public health worldwide.
Nikolay is deeply passionate about inventing, developing, and applying transformative technologies for societal benefit and public health. His extensive scientific background spans entomology, evolution, genetics, molecular biology, and genetic engineering. He is also the inventor of numerous genetic tools, reagents, and technologies that drive innovation in the field.
Synvect is seeking individuals with extensive experience in husbandry, genetics, and transgenesis of Aedes, Culex, and Anopheles mosquitoes. If you’re interested in joining the Synvect team to scale transformative technologies aimed at eradicating malaria, dengue, and other global killers, please don’t hesitate to reach out!
Prefix Maintenance | $7,500,000 | (Apr 15, 2026)
nEye.ai | $80,000,000 | (Apr 15, 2026)
Sygaldry Technologies | $105,000,000 | (Apr 15, 2026)
Smartwage Società Benefit | $2,000,000 | (Apr 15, 2026)
Convelio | Undisclosed Amount | (Apr 15, 2026)
Neato® | $25,000,000 | (Apr 15, 2026)
Synera | $40,000,000 | (Apr 15, 2026)
Turion Space | $75,000,000 | (Apr 15, 2026)
Helical | $10,000,000 | (Apr 15, 2026)
Remission Medical | Undisclosed Amount | (Apr 14, 2026)
Slate Auto | $650,000,000 | (Apr 14, 2026)
Qoro | $750,000 | (Apr 14, 2026)